

REMARKS

Claims 1 and 3-5 have been amended herein, claim 2 has been canceled, and claim 37 has been added. Claims 1 and 3-37 are pending.

Claims 1 and 3-5 have been amended to remove non-elected subject matter therefrom. Claim 2 has been canceled, because the subject matter of claim 2 has been incorporated into claim 1. New claim 37 recites a specific compound included in the elected subject matter.

It is emphasized that none of the claim amendments has been made for reasons related to patentability. Applicants hereby reserve the right to pursue any of the subject matter removed from the claims in one or more continuing applications.

No new matter has been introduced by any of the revisions to the claims.

Restriction Requirement

The Examiner has required restriction under 35 U.S.C. § 121 to one of the inventions I to VI as set forth on pages 2-3 of the Office Action. Group I (claims 1-15, 21-27 and 30-32 drawn to compounds, compositions and method of use where the compounds are of Formula I where X, Y, Z¹, Z² and Z³ are defined to form a 1,6-naphthyridine ring) is elected with traverse with respect to Group V. It is agreed that the inventions defined by Groups I to VI are distinct and that the restriction is proper. However, the restriction requirement is traversed with respect to Group V, because there would be no undue burden involved in the search and examination of Group V with Group I. Group V relates to combinations of compounds of Formula I with HIV infection/AIDS treatment agents. A thorough search for compounds, compositions and uses of the compounds embraced by Group I would necessarily include a search for information on combinations containing compounds embraced by Group I including the combinations encompassed by Group V. It is thus more efficient to do a search and examination of Group V with Group I than not to. Withdrawal of the restriction requirement as applied to Groups I and V is accordingly requested.

Information Disclosure Statements

Attached hereto as Exhibits 1 to 9 are copies of the information disclosure statements mailed on January 10, 2002, January 11, 2002, February 4, 2002, July 10, 2002, February 10, 2003, February 12, 2003, February 24, 2003, April 23, 2003 and July 15, 2003, along with copies of the post cards showing receipt of the statements by the Patent Office. Copies of the documents cited in these statements were sent with the statements. The Examiner is

asked to contact the undersigned as soon as possible if any of the cited documents has not been received, so that arrangements can be made to submit fresh copies.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: August 6, 2003